Picture of Beximco Pharmaceuticals logo

BXP — Beximco Pharmaceuticals News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSuper Stock

Beximco Pharma. - Results for the year ended 30 June 2026


		
		
		
		
		
		
	
	
RNS Number : 2820C
Beximco Pharmaceuticals PLC
09 November 2026
 

9 November 2026

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

BEXIMCO PHARMACEUTICALS PLC.

 

Results for the year ended 30 June 2026

 

Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its audited results for the year ended 30 June 2026.

 

Financial Highlights (consolidated)

 

  • Net revenue increased 14.5% to Bangladesh Taka ("BDT") 56,265.9m / £347.5m (2024-25: BDT 49,120.4m / £295.6m
  • Domestic sales increased 15.1% to BDT 51,852.5m / £320.3m (2024-25: BDT 45,046.9m / £271.1m)
  • Export sales increased 8.3% to BDT 4,413.4m / £27.3m (2024-25: BDT 4,073.5m / £24.5m)
  • Profit after tax increased 30.9% to BDT 9,160.8m / £56.6m (2024-25: BDT 6,998.9m / £42.1m)
  • EPS for the year amounted to BDT 20.17 (2024-25: BDT 15.56)
  • Recommended 60% cash dividend (BDT 6.00 per share)

 

Operational Highlights

 

         Launched 8 generics in 19 presentations in Bangladesh

         2 for the first time in Bangladesh

         Completed 43 new registrations of 36 products across 18 countries worldwide

         Launched anti-migraine drug Eletriptan tablets (20 mg and 40 mg) in the US Market

         Launched Sotalol tablets (80 mg and 160 mg) in the Canadian Market

         Commenced export to Lebanon

         Handed over Triko, the first and only generic copy of breakthrough Cystic Fibrosis drug Trikafta, to patients from 6 countries

 

Post Period Highlights

 

         Launched 5 generics in 6 presentations in Bangladesh

         2 for the first time in Bangladesh

         Completed 9 registrations of 8 products across 6 countries

         Nominated for the “The Scrip Awards 2026” in the category of Community Partnership of the Year

 

Beximco Pharma Managing Director Iqbal Ahmed commented:

 

“We are pleased to announce continued double-digit revenue growth for the financial year. In a challenging macro-economic environment, the delivery of such strong growth is testament to the underlying strength of the business. As always, we have maintained our focus on operational delivery, strengthened our product portfolio and continued to expand our presence in domestic and international markets.

 

“We are especially proud of the Triko launch, the world’s first and only generic copy of breakthrough Cystic Fibrosis drug Trikafta, providing patients with transformative access to a lifesaving medicine at a fraction of the originator price. This launch strongly reflects our commitment to ensuring that patients around the world have access to affordable and high-quality medicines.

 

“Whilst we continue to experience ongoing global macro-economic challenges, we remain focused on executing on our strategy and navigating the evolving business environment.”

 

Exchange rates of £1=Taka 161.9021 for 2025-26 and £1=Taka 166.1585 for 2024-25 have been used in this announcement.

 

The full year accounts can be viewed at the Company's website: www.beximcopharma.com.

 

For further information please visit www.beximcopharma.com or enquire to:

 

Beximco Pharma

S M Rabbur Reza, Chief Operating Officer

Tel: +880 2 58611001, Ext. 20111

 

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, Ext. 20030

 

Mohammad Asad Ullah, FCS

Executive Director & Company Secretary

Tel: +880 2 41060531, Ext. 10140

 

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0)20 3368 3551 / 3555

 

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: +44 (0) 20 3470 0470

 

FTI Consulting 

Simon Conway / Sam Purewal / Lucy Molloy

Tel: +44 (0)20 3727 1000

 

Notes to Editors

 

About Beximco Pharmaceuticals PLC.

 

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company’s broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

 

Beximco Pharma’s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.

 

 

Beximco Pharmaceuticals PLC. and its Subsidiaries

Consolidated statement of financial position

As at 30 June 2026

 

 

30 June 2026

 

Amount in Taka

 

30 June 2025

ASSETS

 

 

 

 

 

 

 

Property, plant and equipment

45,602,684,285

 

43,541,872,125

Right-of-use assets

359,772,325

 

485,613,049

Intangible assets

4,551,852,390

 

4,694,133,629

Deferred tax asset

19,651,021

 

44,078,388

Goodwill

674,570,185

 

674,570,185

Investment in associates

15,364,734

 

-

Other investments

6,733,457

 

20,974,134

Total non-current assets

51,230,628,397

 

49,461,241,510

 

 

 

 

Inventories

13,988,598,555

 

13,586,475,819

Spares and supplies

1,010,233,353

 

799,643,860

Trade and other receivables

3,669,562,137

 

3,628,788,364

Loans, advances, deposits and prepayments

3,220,129,543

 

2,814,492,520

Advance income tax

402,401,544

 

356,507,571

Short term investment

950,000,000

 

900,000,000

Cash and cash equivalents

6,668,012,479

 

1,700,096,960

Total current assets

29,908,937,611

 

23,786,005,094

TOTAL ASSETS

81,139,566,008

 

73,247,246,604

 

 

 

 

EQUITY AND LIABILITIES

 

 

 

Share capital

4,461,120,890

 

4,461,120,890

Share premium

5,269,474,690

 

5,269,474,690

Excess of issue price over face value of GDRs

1,689,636,958

 

1,689,636,958

Capital reserve on merger

294,950,950

 

294,950,950

Revaluation surplus

1,130,820,610

 

1,133,870,432

Unrealized gain/(loss)

3,908,281

 

18,148,958

Retained earnings

49,241,292,553

 

40,239,934,223

Total shareholders' equity

62,091,204,932

 

53,107,137,101

Non-controlling interest

4,103,149,348

 

3,977,498,766

 

 

 

 

TOTAL EQUITY

66,194,354,280

 

57,084,635,867

 

 

 

 

Long term borrowings-net of current maturity

1,738,988,035

 

1,503,595,560

Liability for gratuity and WPPF

3,395,313,958

 

3,688,238,284

Deferred tax liability

2,758,009,938

 

2,575,780,261

Non-current liabilities

7,892,311,931

 

7,767,614,105

 

 

 

 

Short term borrowings

2,303,467,001

 

2,025,393,637

Long term borrowings-current maturity

586,628,854

 

1,436,751,660

Trade and other payables

1,952,971,347

 

2,927,851,030

Accrued expenses

1,422,556,087

 

1,174,096,256

Dividend payable

137,953,976

 

302,271,608

Income tax payable

649,322,532

 

528,632,441

Total current liabilities

7,052,899,797

 

8,394,996,632

Total liabilities

14,945,211,728

 

16,162,610,737

TOTAL EQUITY AND LIABILITIES

81,139,566,008

 

73,247,246,604

 

 

 

Beximco Pharmaceuticals PLC. and its Subsidiaries

Consolidated statement of profit or loss and other comprehensive income

For the year ended 30 June 2026

 

 

 

 

 

Amount in Taka

 

 

 

 

 

 

 

30 June 2026

 

30 June 2025

 

 

 

 

 

Net revenue

 

56,265,856,224

 

49,120,354,035

Cost of goods sold

 

(28,870,192,837)

 

(26,825,860,744)

Gross profit

 

27,395,663,387

 

22,294,493,291

 

 

 

 

 

General and administrative expenses

 

(1,554,380,986)

 

(1,401,982,177)

Selling, marketing and distribution expenses

 

(13,395,060,921)

 

(11,044,794,908)

Operating expenses

      

(14,949,441,907)

 

(12,446,777,085)

Profit from operations

 

12,446,221,480

 

9,847,716,206

 

 

 

 

 

Other income

 

790,337,629

 

608,998,701

Finance cost

 

(656,352,588)

 

(991,706,942)

Share of profit of associates

 

15,364,734

 

-

Profit before tax and WPPF

 

12,595,571,255

 

9,465,007,965

Contribution to WPPF

 

(609,711,618)

 

(460,957,986)

 

 

 

 

 

Profit before tax

 

11,985,859,637

 

9,004,049,979

Current tax

 

(2,617,477,105)

 

(1,986,172,572)

Deferred tax

 

(207,542,476)

 

(19,007,698)

Income tax expenses

 

(2,825,019,581)

 

(2,005,180,270)

Profit after tax

 

9,160,840,056

 

6,998,869,709

 

 

 

 

 

Owners of the Company

 

8,997,423,076

 

6,940,622,589

Non-controlling interest

 

163,416,980

 

58,247,120

Profit/(loss) attributable

 

9,160,840,056

 

6,998,869,709

Other comprehensive income/(loss)

 

(14,240,677)

 

762

Total comprehensive income

 

9,146,599,379

 

6,998,870,471

 

 

 

 

 

Owners of the Company

 

8,983,182,399

 

6,940,623,351

Non-controlling interest

 

163,416,980

 

58,247,120

Total comprehensive income attributable

 

9,146,599,379

 

6,998,870,471

 

 

 

 

 

Earnings per share (EPS)

 

20.17

 

15.56

 

 

 

 

 

 

 


 

Beximco Pharmaceuticals PLC. and its Subsidiaries

Consolidated statement of changes in equity

For the year ended 30 June 2026

 

For the year ended 30 June 2026

Amount in Taka

 

 

 

Share capital

 

Share premium

 

Excess of issue price over face value of GDRs

 

Capital reserve on merger

 

Revaluation surplus

 

Unrealized gain/(loss)

 

Retained earnings

Equity attributable to owners of the Company

 

Non-controlling interests

 

Total

Balance as on 01 July 2025

4,461,120,890

5,269,474,690

1,689,636,958

294,950,950

1,133,870,432

18,148,958

40,239,934,223

53,107,137,101

3,977,498,766

57,084,635,867

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive income:

 

Profit for the year

-

-

-

-

-

-

8,997,423,076

8,997,423,076

163,416,980

9,160,840,056

Other comprehensive income/(loss)

-

-

-

-

-

(14,240,677)

-

(14,240,677)

-

(14,240,677)

Transactions with the shareholders:

 

Cash dividend

-

-

-

-

-

-

-

-

(37,766,398)

(37,766,398)

Others:

 

Adjustment for depreciation on revalued assets

-

-

-

-

(3,935,254)

-

3,935,254

-

-

-

Adjustment for deferred tax on revalued assets

-

-

-

-

885,432

-

-

885,432

-

885,432

Balance as on 30 June 2026

4,461,120,890

5,269,474,690

1,689,636,958

294,950,950

1,130,820,610

3,908,281

49,241,292,553

62,091,204,932

4,103,149,348

66,194,354,280

Net asset value (NAV) per share                                                                                                                                                                                                   139.18             

For the year ended 30 June 2025  

 

 

Share capital

 

Share premium

 

Excess of issue price over face value of GDRs

 

Capital reserve on merger

 

Revaluation surplus

 

Unrealized gain/(loss)

 

Retained earnings

Equity attributable to owners of the Company

 

Non-controlling interests

 

Total

Balance as on 01 July 2024

4,461,120,890

5,269,474,690

1,689,636,958

294,950,950

1,137,305,789

18,148,196

35,079,327,271

47,949,964,744

3,952,938,136

51,902,902,880

Total comprehensive income:

 

 

 

 

 

 

 

 

 

 

Profit for the year

-

-

-

-

-

-

6,940,622,589

6,940,622,589

58,247,120

6,998,869,709

Other comprehensive income/(loss)

-

-

-

-

-

762

-

762

-

762

Transactions with the shareholders:

Cash dividend

-

 

 

 

 

 

(1,784,448,356)

(1,784,448,356)

(33,686,490)

(1,818,134,846)

Others:

Adjustment for depreciation on revalued assets

-

-

-

-

(4,432,719)

-

4,432,719

-

-

-

Adjustment for deferred tax on revalued assets

-

-

-

-

997,362

-

-

997,362

-

997,362

Balance as on 30 June 2025

4,461,120,890

5,269,474,690

1,689,636,958

294,950,950

1,133,870,432

18,148,958

40,239,934,223

53,107,137,101

3,977,498,766

57,084,635,867

Net asset value (NAV) per share                                                                                                                                                                                                      119.04                      

 


 


 

 

Beximco Pharmaceuticals PLC. and its Subsidiaries

Consolidated statement of cash flows

For the year ended 30 June 2026

 

 

30 June 2026

 

Amount in Taka

 

30 June 2025

Cash flows from operating activities:

 

 

 

 

 

 

 

Cash receipts from customers and others

56,660,083,852

 

49,891,648,809

Cash paid to suppliers and employees

(44,249,161,693)

 

(39,742,461,113)

Cash generated from operations

12,410,922,159

 

10,149,187,696

 

 

 

 

Interest paid

(652,368,635)

 

(976,729,205)

Interest received

298,941,277

 

19,922,699

Income tax paid

(2,542,680,987)

 

(1,969,795,120)

Net cash generated from operating activities

9,514,813,814

 

7,222,586,070

 

 

 

 

Cash flows from investing activities:

 

 

 

Acquisition of property, plant and equipment

(3,812,442,309)

 

(2,781,313,389)

Intangible assets

(233,252,022)

 

(247,936,908)

Disposal of property, plant and equipment

11,223,226

 

60,327,928

Disposal of intangible assets

18,255,000

 

-

Dividend received

1,088,746

 

974,510

Short term investment

(50,000,000)

 

(700,000,000)

Net cash used in investing activities

(4,065,127,359)

 

(3,667,947,859)

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

Net increase/(decrease) in long term borrowings

(559,616,178)

 

(152,518,998)

Net increase/(decrease) in short term borrowings

278,073,364

 

(971,266,326)

Dividend paid

(202,084,029)

 

(1,603,086,311)

Net cash from/(used in) financing activities

(483,626,843)

 

(2,726,871,635)

Increase/(decrease) in cash and cash equivalents

4,966,059,612

 

827,766,576

Opening cash and cash equivalents

1,700,096,960

 

854,105,649

Effect of exchange rate changes on cash and cash equivalents

1,855,907

 

18,224,735

Closing cash and cash equivalents

  6,668,012,479

 

1,700,096,960

 

 

 

 

Net operating cash flows per share

21.33

 

16.19

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FR FLFETLSLTIIR

Recent news on Beximco Pharmaceuticals

See all news